Discovery of an Inherited Variant Associated with Susceptibility to Secondary Acute Lymphoblastic Leukemia (ALL) after Lenalidomide Maintenance and Autologous HCT for Multiple Myeloma (MM)

An increased risk of ALL second primary malignancy (SPM) has been observed with lenalidomide maintenance therapy after autologous HCT (len-post-autoHCT) for MM. Lenalidomide exerts its therapeutic effects via cereblon-mediated downregulation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Inherited susceptibility variants in IKZF1 have been described for de novo ALL. We performed a case-control germline targeted sequencing study of the entire IKZF1 and IKZF3 genes with mean coverage ∼2,200X to investigate inherited susceptibility to ALL SPM risk.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Qianqian Zhu, Megan Herr, Shuyi Liang, Qiang Hu, Prashant K Singh, Xinyu Gao, Marcelo C. Pasquini, Jessica T. Leonard, Ashley Rosko, Ruthee-Lu Bayer, Amrita Krishnan, Edward A. Stadtmauer, Richard T. Maziarz, Phillip L McCarthy, Theresa E. Hahn Tags: 118 Source Type: research